Milla Pharmaceuticals Inc. and the Alter Pharma Group
Announce First Paragraph IV Filing
and Acceptance by FDA

Press Release

Milla Pharmaceuticals Announces Approval
and Launch of a Generic Version of Sodium
Acetate Injection 2MEQ/mL by Pfizer Inc.

Press Release

Milla Pharmaceuticals

Injectable and solution
products for hospitals and clinics.

About us

Products

About Milla

Milla Pharmaceuticals is engaged in the development, licensing / acquisition and
commercialization of generic prescription drugs for the U.S. market focused
on niche injectable and solution products for hospitals and clinics.
Our goal is to deliver high quality medicines; via a world-class supply chain,
at affordable prices by leveraging global partnerships with FDA-approved manufacturing facilities from
around the world.

About us

Partner with Milla

We are excited to partner with high-quality pharmaceutical developers and manufacturers that enjoy a collaborative relationship and value our expertise in product selection, market analysis, R&D, regulatory, quality and operations.

We are open to various partnership arrangements, such as:

Co-Development

Licensing

Acquisition of NDAs/ANDAs

Authorized Generics

Give us a Call
Send us a Message
Our location

Minnetonka, Minnesota 55305

Milla Pharmaceuticals Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc.

- Company granted 180-days of exclusivity under FDA Competitive Generic Therapy approval pathway - Milla Pharmaceuticals, a subsidiary of the...
Read More
Milla Pharmaceuticals Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc.

Launch of Dexmedetomidine Hydrochloride Injection in the U.S. Market

We are excited to announce that we have launched the generic version of Precedex® (Dexmedetomidine Hydrochloride Injection) in partnership with Sagent...
Read More
Launch of Dexmedetomidine Hydrochloride Injection in the U.S. Market

New Sodium Acetate Injection Concentration

And another achievement, enhancing medicines accessibility! A.forall, is proud to announce that its U.S. partner, Woodward Pharma Services LLC, has just...
Read More
New Sodium Acetate Injection Concentration

Launch of a Generic Version of Pyridostigmine Bromide Syrup

We are proud to announce that Milla Pharmaceuticals Inc., an A.forall company, in partnership with Acella Pharmaceuticals LLC, has successfully...
Read More
Launch of a Generic Version of Pyridostigmine Bromide Syrup

Milla Pharmaceuticals Inc. a subsidiary of Alter Pharma Group is Becoming A.forall

The Alter Pharma Group is excited to announce its rebranding, uniting all its brands and businesses. We were already sharing...
Read More
Milla Pharmaceuticals Inc. a subsidiary of Alter Pharma Group is Becoming A.forall

Company millestone: Milla Pharmaceuticals Receives FDA Approval for Dexmedetomidine Hydrochloride Injection

We are proud to announce that it has received FDA approval for its generic version of Precedex®, Dexmedetomidine Hydrochloride Injection....
Read More
Company millestone: Milla Pharmaceuticals Receives FDA Approval for Dexmedetomidine Hydrochloride Injection

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of Generic Version of Magnesium Sulfate in Water for Injection

Milla Pharmaceuticals successfully partnered with Athenex Pharmaceutical Division (APD) to release a generic version of Magnesium Sulfate in Water for...
Read More
Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of Generic Version of Magnesium Sulfate in Water for Injection

Milla Pharmaceuticals announces Third ANDA approval and the 4th U.S. approval for the Alter Pharma Group

Milla Pharmaceuticals Inc., announces U.S. Food and Drug Administration (FDA) has granted approval to the Company's Abbreviated New Drug Application...
Read More

Alter Pharma acquires EcoPharmaSupply

The Alter Pharma Group is proud to announce having acquired EcoPharmaSupply (EPS). EPS is a Belgian pharmaceutical services and products company, distributor and...
Read More
Alter Pharma acquires EcoPharmaSupply

Milla Pharmaceuticals Announces Approval of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers.

Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that it has received abbreviated new drug application (ANDA) approval...
Read More
Milla Pharmaceuticals Announces Approval of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers.

A.forall is a Belgian group of pharmaceutical companies with headquarters in Anderlecht (Belgium) and offices in Ireland and the United States. Employing in total 144 employees, the group distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes.

At the same time, A.forall is a global player on the generics market, with around 30 molecules on the European and US market and a fully stocked pipeline of niche, complex and added value products.

We Make Affordable Medicines Available To All

For more information visit A.forall